PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-1.00%
Negative ROE while Drug Manufacturers - Specialty & Generic median is 1.03%. Seth Klarman would investigate if capital structure or industry issues are at play.
-0.87%
Negative ROA while Drug Manufacturers - Specialty & Generic median is 0.34%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
0.67%
ROCE near Drug Manufacturers - Specialty & Generic median of 0.63%. Charlie Munger might conclude industry factors largely shape returns.
97.31%
Gross margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 56.41%. Joel Greenblatt would see if cost leadership or brand drives the difference.
37.70%
Operating margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.86%. Joel Greenblatt would study if unique processes or brand lift margins.
-50.65%
Negative net margin while Drug Manufacturers - Specialty & Generic median is 1.59%. Seth Klarman would see if cost cuts or revenue growth can fix losses.